Alkem Labs: JPMorgan on Alkem Labs Maintains Neutral with Target Price of ₹6,100 as weak India growth, margin pressure from new businesses, and limited near-term earnings catalysts offset improving execution and gross margins.

 17 Aug 2026 08:57 AM

Alkem Labs: JPMorgan on Alkem Labs Maintains Neutral with Target Price of ₹6,100 as weak India growth, margin pressure from new businesses, and limited near-term earnings catalysts offset improving execution and gross margins.

Alkem Labs: Macquarie on Alkem Labs Maintains Underperform with Target Price of ₹4,900 as Q1 revenue missed expectations, India growth lagged the market, Occlutech integration faces delays, and margin improvement is expected to be gradual.

 17 Aug 2026 08:57 AM

Alkem Labs: Macquarie on Alkem Labs Maintains Underperform with Target Price of ₹4,900 as Q1 revenue missed expectations, India growth lagged the market, Occlutech integration faces delays, and margin improvement is expected to be gradual.

Alkem Labs: Investec on Alkem Labs Upgrades to Buy with Target Price of ₹6,400 as attractive valuations, strong Q1 performance, intact FY27 guidance, improving gross margins, and expectations of double-digit India growth support upside potential.

 17 Aug 2026 08:57 AM

Alkem Labs: Investec on Alkem Labs Upgrades to Buy with Target Price of ₹6,400 as attractive valuations, strong Q1 performance, intact FY27 guidance, improving gross margins, and expectations of double-digit India growth support upside potential.

Alkem Lab: Company Approves Investment Of Up To INR 75 Crores.

 14 Aug 2026 01:57 PM

Alkem Lab: Company Approves Investment Of Up To INR 75 Crores.

ALKEM LAB: Q1 CONS NET PROFIT 5.2B RUPEES VS 6.6B (YOY)

 14 Aug 2026 01:47 PM

ALKEM LAB: Q1 CONS NET PROFIT 5.2B RUPEES VS 6.6B (YOY)

ALKEM LAB: Q1 EBITDA 7.7B RUPEES VS 7.4B (YOY) || Q1 EBITDA MARGIN 20.48% VS 21.9% (YOY)

 14 Aug 2026 01:47 PM

ALKEM LAB: Q1 EBITDA 7.7B RUPEES VS 7.4B (YOY) || Q1 EBITDA MARGIN 20.48% VS 21.9% (YOY)

ALKEM LAB: Q1 REVENUE 37B RUPEES VS 33.7B (YOY)

 14 Aug 2026 01:47 PM

ALKEM LAB: Q1 REVENUE 37B RUPEES VS 33.7B (YOY)

Alkem Laboratories: Co To Acquire 51%-55% Stake In Occlutech Holding AG Through Its Subsidiary Alkem Medtech; First Agreement Signed On June 26, 2026.

 29 Jun 2026 09:36 AM

Alkem Laboratories: Co To Acquire 51%-55% Stake In Occlutech Holding AG Through Its Subsidiary Alkem Medtech; First Agreement Signed On June 26, 2026.

Alkem Laboratories: Introduces Semaglutide in Single-Shot Pre-Filled Syringes for Rs. 350; First Company in India to Provide This Format to Make It Easier for Patients.

 02 Jun 2026 03:15 PM

Alkem Laboratories: Introduces Semaglutide in Single-Shot Pre-Filled Syringes for Rs. 350; First Company in India to Provide This Format to Make It Easier for Patients.

Alkem Lab: Nomura Holdings maintains Buy on Alkem Laboratories with target price of ₹6,890; 4Q revenue was in line while EBITDA beat estimates by 11% driven by strong gross margin expansion to 65.4% (+606bps YoY), though PAT was impacted by one-off exceptional losses of ₹1.35bn related to real estate impairment and labour code changes along with a higher tax rate, while FY27 guidance was in line to ahead of expectations and the stock trades at 23.6x/19.7x FY27F/FY28F adjusted EPS.

 29 May 2026 09:08 AM

Alkem Lab: Nomura Holdings maintains Buy on Alkem Laboratories with target price of ₹6,890; 4Q revenue was in line while EBITDA beat estimates by 11% driven by strong gross margin expansion to 65.4% (+606bps YoY), though PAT was impacted by one-off exceptional losses of ₹1.35bn related to real estate impairment and labour code changes along with a higher tax rate, while FY27 guidance was in line to ahead of expectations and the stock trades at 23.6x/19.7x FY27F/FY28F adjusted EPS.

ALKEM LAB: Q4 CONS NET PROFIT RUPEES2.36B VS 3.1B (YOY) || Q4 REVENUE RUPEES 36B VS 31.4B (YOY)

 28 May 2026 01:49 PM

ALKEM LAB: Q4 CONS NET PROFIT RUPEES2.36B VS 3.1B (YOY) || Q4 REVENUE RUPEES 36B VS 31.4B (YOY)

ALKEM LAB: Q4 EBITDA RUPEES 5.17B VS 3.9B (YOY) || Q4 EBITDA MARGIN 14.4 % VS 12.45% (YOY)

 28 May 2026 01:50 PM

ALKEM LAB: Q4 EBITDA RUPEES 5.17B VS 3.9B (YOY) || Q4 EBITDA MARGIN 14.4 % VS 12.45% (YOY)

Alkem Laboratories: Gets 7 Observations From US FDA After Inspecting Daman Facility.

 02 May 2026 01:35 PM

Alkem Laboratories: Gets 7 Observations From US FDA After Inspecting Daman Facility.

Alkem Lab: Co CEO Was Domestic Pharma Business Veteran At Cipla And He Was Brought To Grow Chronic Franchise || Now With His Exit Improvement In Chronic Franchise Seems Gone

 24 Apr 2026 02:53 PM

Alkem Lab: Co CEO Was Domestic Pharma Business Veteran At Cipla And He Was Brought To Grow Chronic Franchise || Now With His Exit Improvement In Chronic Franchise Seems Gone

Alkem Laboratories: Co CEO Dr. Vikas Gupta Resigns To Pursue New Opportunities, Will Stay Until June 30, 2026 For Smooth Handover.

 24 Apr 2026 02:28 PM

Alkem Laboratories: Co CEO Dr. Vikas Gupta Resigns To Pursue New Opportunities, Will Stay Until June 30, 2026 For Smooth Handover.

Alkem Laboratories: Incorporates Its Wholly Owned Dubai Subsidiary, Alkem Pharma Trading FZCO, In The UAE

 13 Apr 2026 03:43 PM

Alkem Laboratories: Incorporates Its Wholly Owned Dubai Subsidiary, Alkem Pharma Trading FZCO, In The UAE

Alkem Laboratories: Launches “A To Z Daily,” A New Multivitamin For Energy, Immunity, And Stress Support.

 07 Apr 2026 03:27 PM

Alkem Laboratories: Launches “A To Z Daily,” A New Multivitamin For Energy, Immunity, And Stress Support.

Alkem Laboratories: Board Approves Bigger Investment For New Greenfield Formulations Plant In Ujjain, Rises To ₹1,036 Crores From ₹533 Crores, To Be Done In Phases.

 02 Apr 2026 01:02 PM

Alkem Laboratories: Board Approves Bigger Investment For New Greenfield Formulations Plant In Ujjain, Rises To ₹1,036 Crores From ₹533 Crores, To Be Done In Phases.

Alkem Labs: Company Incorporates A Fully Owned Subsidiary In Dubai Healthcare City, UAE

 30 Mar 2026 05:45 PM

Alkem Labs: Company Incorporates A Fully Owned Subsidiary In Dubai Healthcare City, UAE

Alkem Lab: Launches Semaglutide Injection In India With Weekly Treatment Cost Of INR 450

 21 Mar 2026 12:39 PM

Alkem Lab: Launches Semaglutide Injection In India With Weekly Treatment Cost Of INR 450